| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Research and development | 2,239 | 4,739 | 4,156 | |
| General and administrative | 5,314 | 2,550 | 3,432 | |
| Total cost and expenses | 7,553 | 7,289 | 7,588 | |
| Operating loss | -7,553 | -7,289 | -7,588 | |
| Interest income | 537 | 607 | 713 | |
| Interest expense | - | - | 129 | |
| Gain on extinguishment of borrowings | - | - | 5,203 | |
| Foreign currency exchange (loss) gain, net | -166 | -1,885 | -1,453 | |
| Total other income (expense), net | 371 | -1,278 | 4,334 | |
| Net loss before taxes | -7,182 | -8,567 | -3,254 | |
| Income tax expense | 6 | 72 | 225 | |
| Net loss | -7,188 | -8,639 | -3,479 | |
| Foreign currency translation adjustment | -456 | 2,349 | 978 | |
| Comprehensive loss | -7,644 | -6,290 | -2,501 | |
| Earnings per share, basic | -0.27 | -0.32 | -0.13 | |
| Earnings per share, diluted | -0.27 | -0.32 | -0.13 | |
| Weighted average number of shares outstanding, basic | 26,899,122 | 26,899,122 | 26,892,575 | |
| Weighted average number of shares outstanding, diluted | 26,899,122 | 26,899,122 | 26,892,575 | |
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (LVTX)